FDA issues warning for compounded drugs from Cantrell Drug Company
Editor's Note
The Food & Drug Administration (FDA) on March 2 issued a warning for healthcare professionals not to use drug products produced by Cantrell Drug Company (Little Rock, Arkansas), including opioids and other drugs intended for sterile injections.
The FDA is concerned about serious deficiencies in Cantrell’s compounding operations, including processes to ensure quality and sterility assurance.
Posted 03/02/2018] AUDIENCE: Patient, Health Professional, Risk Manager ISSUE: FDA is alerting health care professionals and patients not to use drug products produced by Cantrell Drug Company of Little Rock, Arkansas, including opioid products and other drugs intended for sterile injection, that were produced by the company and distributed nationwide.
Free Daily News
- Survey assesses continued impact of Change Healthcare cyberattack
- WHO sounds alarm on potential spread of bird flu
- Allison Massari to deliver hopeful, empowering keynote address at OR Manager Conference 2024
- Neurosurgery trial: Early evacuation improves long-term hemorrhage outcomes
- Drug shortages higher than ever
- FDA announces class 1 recalls for premixed embolic, infusion pump software
- Academic medical centers identify performance-improvement priorities
- Propofol anesthesia for colonoscopy could help find polyps, prevent cancer
- FDA Class 1 recall renews concern about historically problematic heart pumps
- New physician compensation report reveals modest pay gains but growing discontent with the profession